

Lightning Talks II

6:30 p.m.-7:15 p.m. | Essex Ballroom

Session Chair: Patrick G. Pilie, MD Anderson Cancer Center, Houston, Texas

1. **Spatial heterogeneity atlas of prostate cancer evolution (SHAPE): Spatial and genomic landscapes of advanced prostate cancer with and without Lu-PSMA therapy***
 Martin Bakht
 Dana-Farber Cancer Institute, Boston, MA
2. **Unveiling the metabolic profiles of prostate cancer to anticipate patient response to treatment***
 Andrea Brunello
 University of Bern, Bern, Switzerland
3. **Integrating multi-omic datasets investigating stress response biology decodes prostate cancer dynamic disease progression and places IRE1 activity at the epicentre of acquired treatment resistance***
 Dimitrios Doultzinos
 University of Oxford, United Kingdom
4. **Baseline prostate-specific antigen levels in men aged 65 to 80 and fatal prostate cancer: Implications for risk-stratified screening among older men***
 Hannah E. Guard
 Harvard TH Chan School of Public Health, Boston, MA
5. **Therapeutic targeting of eIF4E cap-binding domain reveals control of lineage fate in prostate cancer***
 Rashmi Mishra
 Fred Hutch Cancer Center, Seattle, WA
6. **NSD2 inhibition in hormone-sensitive prostate cancer synergizes with androgen deprivation therapy to improve tumor response***
 Zachery Schultz
 University of Wisconsin-Madison, Madison, WI
7. **Cooperativity between DNA methylation and EZH2 activity drives neuroendocrine phenotype in advanced prostate cancer***
 Richa Singh
 Weill Cornell Medicine, New York, NY
8. **The TIP60 acetyltransferase complex is a critical dependency in neuroendocrine prostate cancer through its role as a critical coactivator of MYCL downstream of ASCL1***
 Zhen Sun
 Memorial Sloan Kettering Cancer Center, New York, NY